Doubling down on its previous investment in the company is Menlo Ventures, which along with the growth-stage investment firm IVP co-led the new financing for the company.
Their rationale for investing can be attributed to H1’s explosive growth. The company now has 250 employees after launching from Y Combinator just 12 months ago. Already a player in the U.S., H1 is looking to expand to Europe and Asia in 2021, and counts 13 of the top 20 pharmaceutical companies as its clients. As of its last tally, the company already had profiles on more than 9 million healthcare professionals worldwide.
According to one person with knowledge of the company’s fundraising history, Menlo Ventures was so pleased with the company’s performance that it offered tens of millions of dollars in pre-emptive financing.